...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
Message: BIO Investor Forum, Oct 22-23

,,,hummm,,,is there any chance some of our oncology trial data will accompany these presentations??........it probably matters not short term cuz we really are held at arms length from our shares,,,,,,,,yet,,,some nice data would add a special touch to these Fall colors at this time of year,,,and before Xmas,,,,,,,,,and 2020.,,,,,

Share
New Message
Please login to post a reply